Abbott Laboratories said on Friday that it won U.S. marketing approval for a diagnostic test for the COVID-19 that can deliver results within minutes and be used in physicians offices and urgent care clinics, as well as hospitals.
The United States now has more cases of the COVID-19 than any other country, and hospitals are struggling to meet the demand to test thousands of people for the often-deadly virus.
The U.S. Food and Drug Administration granted the approval under its Emergency Use Authorization.
Abbott said in a statement that it plans to begin distributing the test next week and will ramp up manufacturing to 50,000 tests per day.
“This is a significant leap forward,” John Frels, vice president of research and development at Abbott, said in an interview with Reuters . “You can get a positive result in five minutes and a negative result in 13 minutes. You can walk into a clinic and literally get results while you are there.”
The portable test will run on Abbott's ID NOW platform.
It is the second test to be approved by the FDA that can be used directly in physicians' offices and other community healthcare settings and promptly provide results to patients. Last week, the FDA approved a test made by Cepheid that can be used at the point of care.
“The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Robert Ford, president and chief operating officer at Abbott, in a statement.
Abbott received approval last week for a high volume, automated diagnostic test that can be used in laboratories and said at the time it would immediately distribute 150,000 of the tests around the country.
Between the two platforms, Abbott said it plans to produce 5 million tests per month.
The FDA has been rushing to approve tests for the coronavirus on an emergency basis and has approved others made by companies including Roche Holding AG and Thermo Fisher Scientific Inc.
